Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D
Oral-Periodontal Evaluation and Assessment of Biomarkers in Oral Fluids in Patients With Hepatitis B+D Treated With Bulevirtide
Research Center of Periodontal-Systemic Interactions
25 participants
Feb 15, 2026
OBSERVATIONAL
Summary
Periodontal disease is a chronic inflammatory condition associated with systemic diseases, highlighting the concept of periodontal medicine. This study aims to investigate the relationship between periodontal inflammation, oral lesions, and hepatitis B+D infection, with or without bulevirtide treatment. Oral-periodontal clinical parameters and targeted inflammatory biomarkers in saliva and gingival crevicular fluid will be evaluated in three groups: patients with hepatitis B+D receiving bulevirtide, patients with hepatitis B+D not receiving bulevirtide, and healthy controls.
Eligibility
Inclusion Criteria6
- Adults (≥18 years old) capable of providing informed consent.
- For Hepatitis B+D groups: confirmed hepatitis B and D co-infection.
- Bulevirtide group: receiving bulevirtide therapy as prescribed.
- No Bulevirtide group: not receiving bulevirtide.
- For Healthy Control group: systemically healthy adults without hepatitis B or D infection.
- Willingness to undergo oral-periodontal examination, saliva and gingival crevicular fluid collection, and oral cavity photography.
Exclusion Criteria5
- Patients with other systemic diseases that could influence periodontal health (e.g., uncontrolled diabetes, autoimmune diseases).
- Patients currently receiving other experimental therapies that may affect oral or systemic inflammation.
- Pregnancy or lactation.
- Inability or unwillingness to provide informed consent.
- History of oral or periodontal surgery within the last 6 months that could affect measurements.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Bulevirtide is an entry inhibitor used for the treatment of hepatitis B and D virus co-infection. In this observational study, patients receiving bulevirtide therapy as part of their routine clinical care will be evaluated for oral-periodontal clinical parameters and inflammatory biomarkers in saliva and gingival crevicular fluid.
Patients diagnosed with hepatitis B+D who are not receiving bulevirtide therapy and are evaluated for comparison of oral-periodontal parameters and biomarkers.
Systemically healthy individuals without hepatitis B or D infection serving as the control group for comparison of oral-periodontal parameters and inflammatory biomarkers.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07491848